Accumulating evidence indicates tumor necrosis factor-alpha (TNF-alpha) as a key cytokine in the pathogenesis of the myelodysplastic syndromes (MDS). The identification of TNF-alpha as a regulator of apoptosis and the increased susceptibility of MDS cells to this cytokine provided the basis for several clinical trials of TNF inhibitors. Infliximab is an IgG(1) chimeric anti-TNF-alpha monoclonal antibody composed of human constant and murine variable regions that bind specifically to both soluble and membrane-bound TNF-alpha. To date, only 2 studies have investigated the use of infliximab in patients with low-risk MDS. In both reports the drug showed a limited but significant activity and a favorable side-effect profile. In some patients, hematopoietic response was associated with decreased apoptosis as well as a decrease in abnormal metaphases by 50%. Further studies are currently underway and should provide useful information to de. ne the more responsive subtypes of MDS, the patient characteristics, and the proper dosing regimen.
|Tipologia:||Articolo su rivista|
|Citazione:||Stasi R., A.S. (2005). Infliximab chimeric antitumor necrosis factor-alpha monoclonal antibody as potential treatment for myelodysplastic syndromes. LEUKEMIA & LYMPHOMA, 46(4), 509-516.|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Revisione (peer review):||Sì, ma tipo non specificato|
|Digital Object Identifier (DOI):||10.1080/10428190400027829|
|Stato di pubblicazione:||Pubblicato|
|Data di pubblicazione:||2005|
|Titolo:||Infliximab chimeric antitumor necrosis factor-alpha monoclonal antibody as potential treatment for myelodysplastic syndromes|
|Autori interni:||AMADORI, SERGIO|
|Autori:||Stasi R., Amadori S., Newland A.C., Provan D.|
|Appare nelle tipologie:||01 - Articolo su rivista|
File in questo prodotto:
- PubMed Central loading...